Novo Nordisk takes a hit as CagriSema underperforms in weight loss Novo Next Generation Obesity Shot Falls Short of Lilly Rival Bloomberg No change' for CagriSema as Novo ditches single chamber device Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues Novo Nordisk Stock Tumbles on CagriSema Trial Data. Why Investors Have Doubts. Barron's